

Product Data Sheet

Product Name: GNE 0723

Cat. No.: GC31270

Chemical Properties

Cas. No. 1883518-31-7

SMILES N#C[C@H]1[C@H](C2=C(C(F)(F)F)SC3=NC(CN4N=C(C(F)(F)F)C=C4Cl)=CC(N32)=O)C1


Formula $C_{16}H_8ClF_6N_5OS$ M.Wt 467.78

Solubility DMSO : 190 mg/mL (406.17 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Protocol

Cell experiment [1]:

Cell lines CHO cell lines

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Whole-cell patch-clamp recordings were made from CHO cell lines, 1 μ M GNE 0723 and 0.03-100 μ M Glu was applied for a 5ms pulse duration using a 2-barrel theta tube perfusion system with a P-601.30L PiezoMove linear actuator.

Reaction
Conditions 1 μ M

Applications GNE 0723 at 1 μ M enhanced NMDAR currents evoked by a wide range of Glu concentrations.

Animal experiment [1]:

Animal models Sex-mixed 4–6-month-old J20

Doses of GNE 0723 were administered via oral gavage as 0.5% methylcellulose and 0.2% Tween 80 (MCT) suspension. Vehicle was used as control. Drug doses for GNE 0723 are expressed as mg/kg of free base.

Dosage form 3mg/kg; oral; every other day for 5 weeks.

Applications An early probe trial 24 h after 3 days of MWM training revealed a significant quadrant preference (reference memory) in GNE 0723-treated J20 mice.

References:

[1]. Hanson, Jesse E., et al. "GluN2A NMDA receptor enhancement improves brain oscillations, synchrony, and cognitive functions in Dravet syndrome and Alzheimer's disease models." Cell reports 30.2 (2020): 381-396.

Background

GNE 0723 is a GluN2A subunit-selective and brain-penetrant positive allosteric modulator (PAM) of NMDARs, with an EC₅₀ of 0.021 μ M and a maximal potentiation of 152%^[1,2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In vitro, Whole-cell recordings at room temperature (RT) from CHO cells expressing GluN2A-containing NMDARs showed that 1 μ M GNE 0723 enhanced the peak current and slowed the current deactivation in response to brief pulses of glutamate (Glu)^[3].

In vivo, mouse clearance of GNE 0723 was 26 mL·min⁻¹·kg⁻¹ and oral bioavailability was 24%^[1]. GNE 0723 (3mg/kg; oral; every other day for 5 weeks) treatment improved memory retention in J20 mice and improved long-term memory consolidation in J20 and WT mice by the Morris water maze (MWM) test^[3]. GNE 0723 (3mg/kg; oral; every other day for 5 weeks) enhances fear learning in Scn1a-KI mice^[3].

References:

- [1]. Villemure, Elisia, et al. "GluN2A-selective pyridopyrimidinone series of NMDAR positive allosteric modulators with an improved in vivo profile." ACS Medicinal Chemistry Letters 8.1 (2017): 84-89.
- [2]. Li, Zhongtang, et al. "Discovery of novel and potent N-methyl-D-aspartate receptor positive allosteric modulators with antidepressant-like activity in rodent models." Journal of Medicinal Chemistry 64.9 (2021): 5551-5576.
- [3]. Hanson, Jesse E., et al. "GluN2A NMDA receptor enhancement improves brain oscillations, synchrony, and cognitive functions in Dravet syndrome and Alzheimer's disease models." Cell reports 30.2 (2020): 381-396.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA